1 / 116

Medical Alley Advanced Monitoring Workshop

Medical Alley Advanced Monitoring Workshop. Paul Below P. Below Consulting, Inc. October 19, 2005. Disclosure. The presenter does not have a significant equity interest in any of the companies/products referenced here The presenter has a consulting relationship with the following:

stesha
Download Presentation

Medical Alley Advanced Monitoring Workshop

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Medical Alley Advanced Monitoring Workshop Paul Below P. Below Consulting, Inc. October 19, 2005

  2. Disclosure • The presenter does not have a significant equity interest in any of the companies/products referenced here • The presenter has a consulting relationship with the following: • GlaxoSmithKline • Boehringer Ingelheim Pharmaceuticals • Southeast Louisiana Chapter ACRP

  3. This presentation and related references are posted on my website at: www.pbelow-consulting.com/monitoring.html

  4. Objectives • The role of monitoring in Good Clinical Practices (GCPs) • Activities involved in on-site visits • Common site problems and findings • Addressing non-compliance • Fraud and misconduct • Electronic records

  5. Objectives • Interactive case studies of real-life monitoring situations

  6. The Role of Monitoring in Good Clinical Practices

  7. Why Do We Monitor? • Required to by regulation • Ensure the acceptance of trial data by regulatory authorities (i.e., FDA)

  8. Why Do We Monitor? • Verify that rights and well-being of human subjects are protected • Verify that reported data are accurate, complete and verifiable • Verify trial is conducted in compliance with protocol, GCP and applicable regulatory requirements

  9. Good Clinical Practice • “A unified standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects” • Federal regulations (Title 21 CFR) • Other federal regulations & state laws • FDA “guidance documents”

  10. GCP Regulations • Protection of human subjects - informed consent (part 50) • Institutional review boards (part 56) • Financial disclosure (part 54) • Electronics records and signatures (part 11) • Investigational new drugs (part 312) and application to market a new drug (part 314) • Investigational device exemptions (part 812) & premarket approval of medical devices (part 814)

  11. Other Federal Regulations • Nuclear Regulatory Commission regulations (10 CFR 35) for the medical use of radioactive substances • Department of Transportation regulations for the shipment of infectious materials (49 CFR) • HIPAA Privacy Rule (45 CFR 160-164) for the use and disclosure of protected health information

  12. State Laws • Many states have laws that impact clinical research in the following areas: • Age of consent • Legally authorized representative • Clinical research registration • Medical records privacy • Gene research • STD/HIV reporting

  13. GCP Guidance Documents • FDA Information Sheets (www.fda.gov/oc/ohrt/irbs/default.htm) • Guideline for the Monitoring Clinical Investigations (January 1988) • ICH Guidelines for Good Clinical Practice (Published in Federal Register - May 9, 1997)

  14. FDA Guidance • Represents the agency’s “current thinking” on how to comply with the regulations • Not legally binding • Non-compliance should not be cited in a FDA Form 483 • An alternative approach can be used if acceptable to FDA

  15. What is ICH? • International Conference on the Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use • Comprised of representatives from the U.S., European Union and Japan • Establish guidelines to promote mutual acceptance of data

  16. Monitoring Requirement • “Sponsors are responsible for … ensuring proper monitoring of the investigation” (812.40 and 312.50) • “The sponsor shall monitor the progress of all investigations involving an exception to informed consent” (812.47 and 312.54)

  17. Monitoring Plan • For significant risk device and treatment use trials, FDA requires written procedures for monitoring in the investigational plan (812.25, 812.40) • FDA can withhold or pull approval of an application if the monitoring plan is inadequate (812.30)

  18. Monitoring Plan (cont) • Monitoring plan based on: • Trial objectives, design, endpoints • Trial complexity • Number/location of investigators • Type of investigational product • Disease under study

  19. Type of Monitoring • “Personal contact” should be maintained with the investigator throughout the trial • Need for on-site visits before, during and after the trial • In exceptional circumstances, central monitoring can be used

  20. Selection of Monitors • “A sponsor shall select monitors qualified by training and experience” (812.43) • A list of names and addresses of all monitors is included with the investigational plan (812.25) • Monitoring functions can be transferred to a CRO (312.52)

  21. Monitor Selection • Need not be qualified to diagnose or treat disease under study • Thoroughly familiar with test article, protocol and informed consent, sponsor’s SOPs, and GCPs and FDA regulations • Qualifications should be documented

  22. Recent FDA Warning Letter “Study monitors were not qualified by training and experience. Neither of the two individuals who conducted monitoring visits for the [redacted] study had previous experience in clinical monitoring; one of the two monitors had no training in clinical trials prior to conducting independent monitoring trials.” CDRH Warning Letter to Celsion Corporation (May 7, 2004)

  23. Outstanding Monitor Traits • Quick scientific learners • Independent problem solvers • Can hack the travel • Can see the forest and the trees • Regulatory experts • Technologically proficient

  24. Activities Involvedin On-Site Visits

  25. On-Site Visit Types • Pre-Investigation • Periodic Monitoring • Close-Out

  26. Selection of Investigators • “A sponsor shall select investigators qualified by training and experience to investigate the device” (812.43)

  27. Investigator Selection • Preliminary phone contacts and on-site visit to determine if the investigator: • Understands and accepts trial obligations • Understands and accepts regulatory obligations • Can demonstrate potential for recruitment based on retrospective data • Has adequate facilities • Has sufficient time • Has adequate number of qualified staff for duration of trial

  28. Investigator Selection • Other Considerations: • Past company performance • Past performance with other sponsors • References from colleagues • Publication record • Key opinion leaders • FDA Debarment and Disqualified Lists • FDA Warning Letters • CDER Clinical Investigator Inspection List

  29. FDA Investigator Lists • Debarment List: • Convicted of a felony under Federal law for conduct relating to development or approval of any drug product • www.fda.gov/ora/compliance_ref/debar/default • Disqualified/Restricted/Assurances Lists: • Disqualified through hearing process or restricted through consent agreement • www.fda.gov/ora/compliance_ref/bimo/dis_res_assur.htm

  30. FDA Investigator Lists • Clinical Investigators Inspection List: • Contains information gathered from inspections of clinical investigators who have performed studies with investigational human drugs • The inspections were conducted as part of FDA’s Bioresearch Monitoring Program • www.fda.gov/cder/regulatory/investigators/default.htm

  31. Pre-Investigation Visit • Location • All facilities where trial conduct will occur • Materials • Investigator’s Manual • Device • Agenda

  32. Pre-Investigation Visit • Participants • Principal Investigator/Co-Investigators • Study coordinator/research nurse • Other medical staff (technicians)

  33. Pre-Investigation Activities • Discussion of device background, protocol procedures • Discussion of resources • Staff availability and training • Adequate time and workload • Interest and motivation level • Available patients (review retrospective data) • Competing trials

  34. Pre-Investigation Activities • Review case report forms and required source documentation • Discussion of regulatory obligations • IRB review • Informed consent • Record keeping • Investigational product • Company policies and procedures

  35. Pre-Investigation Activities • Tour facilities • Patient evaluation and treatment facilities • Emergency facilities and staff • Laboratory • Device storage and security • Files storage (administrative and patient) • Collect investigator documentation

  36. Investigator Documentation • CV and/or statement of relevant experience (812.43) • If involved in a terminated trial, explanation of circumstances (812.43) • Signed Investigator Agreement (812.43) • Financial disclosure information (812.43)

  37. Investigator Documentation • IRB approval documentation (812.42) • Provide the investigator with the investigational plan and report of prior investigations of the device (812.45) • Other records (ICH): • Local lab certification, normal ranges • IRB membership roster • Medical license

  38. Periodic Visit Planning • Participants • Study coordinator • Principal investigator • Technicians • Timing • Follow monitoring plan • Flexibility for problem sites • First visit early

  39. Periodic Visit Planning • Materials • Protocol • List of enrolled patients • Reference manuals • Site specific material/documents • Office supplies • Assigned work space • Assigned time with investigator and trial staff

  40. Periodic Visit Objectives • Review compliance with protocol, GCPs, and sponsor SOPs • Review data • Review investigational product • Verify adequacy of facilities & resources • Review essential (regulatory) documents

  41. Protocol/GCP Compliance • Protocol deviations explained (812.140) • Enrolling only eligible patients • Informed consent obtained before each subject’s trial participation (and case history statement, 812.140) • All required reports to sponsor and IRB • Adverse events appropriately reported

More Related